Buprenorphine/naloxone

Lotus Pharmaceutical, based in Tashkent, Uzbekistan, offers a generic buprenorphine/naloxone sublingual film indicated for the treatment of opioid dependence. This product was the first P4 product launched in the US market, marking a significant milestone in the company’s export portfolio. As a sublingual film formulation, it is designed for administration under the tongue, allowing for rapid absorption of the active ingredients. Buprenorphine, a partial opioid agonist, helps reduce withdrawal symptoms and cravings, while naloxone serves as an antagonist to deter misuse by injection. Such combination products are commonly used in medication-assisted treatment programs by healthcare providers and addiction clinics globally. The manufacturer, established in 1966, has developed this product to meet international pharmaceutical standards for sourcing buyers seeking reliable generics in the treatment of substance use disorders. This entry is relevant for distributors and procurement professionals focused on addiction medicine supply chains.